These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8042825)

  • 1. Limitations of angiography for analyzing coronary atherosclerosis progression or regression.
    Hong MK; Mintz GS; Popma JJ; Kent KM; Pichard AD; Satler LF; Leon MB
    Ann Intern Med; 1994 Sep; 121(5):348-54. PubMed ID: 8042825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials.
    Mack WJ; Azen SP; Dunn M; Hodis HN
    Control Clin Trials; 1997 Apr; 18(2):168-79. PubMed ID: 9129860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of coronary atherosclerosis in patients with mild coronary artery disease studied by serial quantitative coronary angiography at 2 and 4 years follow-up. The Multicenter Anti-Atheroma Study (MAAS) Investigators.
    Vos J; de Feyter PJ; Kingma JH; Emanuelsson H; Legrand V; Winkelmann B; Dumont JM; Simoons LM
    Eur Heart J; 1997 Jul; 18(7):1081-9. PubMed ID: 9243140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.
    Ndrepepa G; Iijima R; Kufner S; Braun S; Cassese S; Byrne RA; Sorges J; Schulz-Schüpke S; Hoppmann P; Fussaro M; Laugwitz KL; Schunkert H; Kastrati A
    Am Heart J; 2016 Jul; 177():9-16. PubMed ID: 27297844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.
    Watts GF; Pang J; Chan DC; Brunt JNH; Lewis B
    Atherosclerosis; 2016 Sep; 252():82-87. PubMed ID: 27508319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remarkable regression of coronary atherosclerosis: An interplay of pharmacotherapeutic and lifestyle factors.
    Chockalingam P; Vinayagam NS; Chockalingam V; Chockalingam A
    Indian Heart J; 2016; 68(2):188-9. PubMed ID: 27133332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
    Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression and regression of the atherosclerotic plaque.
    de Feyter PJ; Vos J; Deckers JW
    Eur Heart J; 1995 Aug; 16 Suppl I():26-30. PubMed ID: 8829954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
    Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
    Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression. The Harvard Atherosclerosis Reversibility Project Study Group.
    Stone PH; Gibson CM; Pasternak RC; McManus K; Diaz L; Boucher T; Spears R; Sandor T; Rosner B; Sacks FM
    Am J Cardiol; 1993 Apr; 71(10):766-72. PubMed ID: 8456751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
    Shukla A; Sharma MK; Jain A; Goel PK
    Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
    Brener SJ; Ivanc TB; Hu T
    J Invasive Cardiol; 2008 Jun; 20(6):261-5. PubMed ID: 18523316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
    Post Coronary Artery Bypass Graft Trial Investigators
    N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT).
    Kleemann A; Eckert S; von Eckardstein A; Lepper W; Schernikau U; Gleichmann U; Hanrath P; Fleck E; Neiss A; Kerber S; Assmann G; Breithardt G;
    Eur Heart J; 1999 Oct; 20(19):1393-406. PubMed ID: 10487800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
    Burton JR; Teo KK; Buller CE; Plante S; Catellier D; Tymchak W; Taylor D; Dzavik V; Montague TJ;
    Can J Cardiol; 2003 Apr; 19(5):487-91. PubMed ID: 12717482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of severe atherosclerotic plaque in patients with mild elevation of LDL cholesterol.
    Schaefer S; Hussein H; Gershony GR; Rutledge JC; Kappagoda CT
    J Investig Med; 1997 Dec; 45(9):536-41. PubMed ID: 9444880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cystatin C levels on angiographic atherosclerosis progression and events among postmenopausal women with angiographically decompensated coronary artery disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study).
    Patel D; Ahmad S; Silverman A; Lindsay J
    Am J Cardiol; 2013 Jun; 111(12):1681-7. PubMed ID: 23499273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study).
    Vigen C; Hodis HN; Selzer RH; Mahrer PR; Mack WJ
    Am J Cardiol; 2005 Jun; 95(11):1277-82. PubMed ID: 15904629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials.
    Gibson CM; Sandor T; Stone PH; Pasternak RC; Rosner B; Sacks FM
    Am J Cardiol; 1992 May; 69(16):1286-90. PubMed ID: 1585861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.